Compare · MDT vs NUWE
MDT vs NUWE
Side-by-side comparison of Medtronic plc. (MDT) and Nuwellis Inc. (NUWE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDT and NUWE operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $127.84B, about 69306.8x NUWE ($1.8M).
- MDT has been more active in the news (14 items in the past 4 weeks vs 9 for NUWE).
- MDT has more recent analyst coverage (25 ratings vs 1 for NUWE).
- Company
- Medtronic plc.
- Nuwellis Inc.
- Price
- -
- -
- Market cap
- $127.84B
- $1.8M
- 1M return
- +3.49%
- -
- 1Y return
- -1.16%
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 14
- 9
- Recent ratings
- 25
- 1
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Nuwellis Inc.
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Brunei, Germany, Greece, Hong Kong, India, Israel, Italy, Palestine, Singapore, Spain, Switzerland, Thailand, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Latest MDT
- Orchestra BioMed to Participate in the Piper Sandler 38th Annual Healthcare Conference
- Medtronic upgraded by Piper Sandler with a new price target
- Medtronic announces FDA clearance of general surgery procedures for the Hugo™ robotic-assisted surgery (RAS) system
- Medtronic to acquire Contego Medical, expanding access to next-generation carotid therapies
- Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
- SEC Form SCHEDULE 13G filed by Medtronic plc.
- Imperative Care Announces Two New Board of Directors Appointments
- Orchestra BioMed Announces Pricing of Public Offering
- Orchestra BioMed Announces Proposed Public Offering
- President Marinaro Michael was granted 6,547 units of Ordinary Shares, increasing direct ownership by 6% to 113,353 units (SEC Form 4)
Latest NUWE
- Nuwellis to Host Webinar Discussing ULTRA-Peds Registry Results and Aquadex Performance in Critically Ill Pediatric Patients
- Nuwellis Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by Nuwellis Inc.
- Nuwellis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Nuwellis Reports Third Quarter 2026 Financial Results and Business Update Highlighted by 430 Basis Point Gross Margin Expansion and 13% Reduction in Operating Expenses, Driving 24% Improvement in Operating Loss
- Nuwellis Secures Exclusive U.S. Distribution Rights for Zorro-Flow® Pediatric Urine Collection System Supporting Non-invasive Urine Collection and Earlier Identification of Acute Kidney Injury in Neonates and Small Children
- Nuwellis Submits FDA 510(k) to Expand Aquadex SmartFlow® Indication to Include Pediatric Patients Weighing 5 kg and Above
- Nuwellis to Report Third Quarter 2026 Financial Results on November 12
- Nuwellis Announces Acceptance of Multicenter Pediatric Aquadex Study in Pediatric Nephrology
- SEC Form 8-K filed by Nuwellis Inc.